Latest Development Program News

Felix Gold has created Frontier Antimony Refinery Corp., a US-focused refining platform with secured access to military-grade antimony ore from its Treasure Creek Project in Alaska, aiming to address critical supply gaps.

Simble Solutions is on the cusp of revealing initial results from its NanoSensor technology development, targeting major markets including Industrial IoT, defence sensing, and wearable medical devices.

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.

Alterity Therapeutics has clinched FDA agreement on the pivotal Phase 3 trial design for ATH434, targeting Multiple System Atrophy, with the trial set to begin by the end of 2026.

VEEM Limited has finished its factory extension and installed new machinery, setting the stage for a stronger second half of FY26 and anticipated growth in FY27 driven by defence contracts and marine propulsion innovations.

Lithium Universe (ASX: LU7) has launched a detailed development program to commercialise a novel hydrometallurgical process for extracting gold and copper from electronic waste, aiming to disrupt traditional smelting with a more sustainable, low-energy method.

Opthea Limited resumes ASX trading as it pivots to develop OPT-302 for lymphangioleiomyomatosis, outlining a disciplined 18-month staged clinical program backed by A$31.2 million in cash.

Swift TV has completed a multi-year Google certification process for its enterprise connected TV platform, validating its technology and supporting ongoing deployments across mining, aged care, and hospitality sectors.

Bounty Oil & Gas NL has locked in A$4.5 million from a heavily oversubscribed share placement, with proceeds earmarked for drilling, facility upgrades, and exploration across its Australian assets.

Racura Oncology has locked in an underwriting agreement covering nearly 1.84 million expiring options, ensuring up to $2.3 million in fresh capital to back its cancer drug development programs.

Actinogen Medical has obtained positive scientific advice from the European Medicines Agency that aligns with prior FDA guidance, clarifying regulatory requirements for its Alzheimer’s drug Xanamem and paving the way for a streamlined approval process in major markets.

Cadoux Ltd has cleared a critical technical and commercial hurdle by qualifying its premiumHPA® high purity alumina for use in the EU-backed SAFELOOP electric vehicle battery project, opening doors to potential offtake deals and boosting its standing in the critical minerals market.